Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc by Lei Wang (6656)

“…Background<p>Pralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …”

The negative ecological impacts of a globally introduced species decrease with time since introduction by Libor Zavorka (828469)

Proteasome activity was decreased in the <i>myc-rpt6-S119A</i> mutant. by Esther Magdalena Marquez-Lona (4183126)

“…<p>(A) Lysates from strains in stationary phase (A₆₀₀>5.0) were subjected to native gel electrophoresis followed by an in-gel activity assay with the fluorogenic proteasome substrate Suc-LLVY-AMC. …”

Deterioration of the anammox process at decreasing temperatures and long SRTs by Maaike Hoekstra (3915545)

Growth on stiff substrate results in mild lifespan extension but a decrease in organismal health. by Maria Oorloff (19658113)

RNA interference-mediated decrease in Ixofin3D results in decreased <i>B. burgdorferi</i> burden in the salivary glands and in murine skin. by Sukanya Narasimhan (73432)

The substitution F447L is adaptive for J4_S52-HVR1, while it decreases infectivity of parental J4 and J4_ΔHVR1 HCVcc. by Christina Holmboe Olesen (11154333)

Pharmacological Mechanism of the Non-hallucinogenic 5‑HT_2A Agonist Ariadne and Analogs by Michael J. Cunningham (14267038)

“…Ariadne is a non-hallucinogenic analog in the phenylalkylamine chemical class of psychedelics that is closely related to an established synthetic hallucinogen, 2,5-dimethoxy-4-methyl-amphetamine (DOM), differing only by one methylene group in the α-position to the amine. …”

Pharmacological Mechanism of the Non-hallucinogenic 5‑HT_2A Agonist Ariadne and Analogs by Michael J. Cunningham (14267038)

“…Ariadne is a non-hallucinogenic analog in the phenylalkylamine chemical class of psychedelics that is closely related to an established synthetic hallucinogen, 2,5-dimethoxy-4-methyl-amphetamine (DOM), differing only by one methylene group in the α-position to the amine. …”

Dcp1a protein levels are decreased by KapB expression and Torin treatment. by Carolyn-Ann Robinson (13297009)

Illustration of the electrophysiological response (steady-state evoked potential) when stimulating with 8 Hz and 36 Hz in, respectively, a young and an old adult from our sample. by Anna Horwitz (771335)

Subjects:

Thalidomide treatment inhibits growth in RAMEC but not in RAMEC transfected with a dominant negative mutant of CUL5 (^S730ACUL5) cDNA. by Bryan Kunkler (5204327)

Diverse stress conditions trigger a rapid and dramatic decrease in miR-520b-3p and a corresponding increase in ATF5 mRNA over time in HeLa cells. by Kari A. Gaither (9046190)

Acetaldehyde decrease/eliminates C/EBP alpha binding to CTSL promoter sequence. by Riyaz A. Mir (350175)

Cardiac overexpression of miR-130a results in decreased FOG-2 expression and a thin ventricular myocardial wall. by Gene H. Kim (371958)

TG6-44 treatment leads to decrease in A/X31-induced cell death in THP-1 cells. by Juan A. De La Cruz (11154187)

Decreased Muscle Strength of Knee Flexors Is Associated With Impaired Muscle Insulin Sensitivity in Non-Diabetic Middle-Aged Japanese Male Subjects by Yuki Someya (770709)

Substrate translocation via Mep2^H194E induces a pH decrease. by Ana Sofia Brito (8463537)

Inclusion of SRRM4-regulated exons is decreased in tumors and cancer cell lines. by Sarah A. Head (6066398)

“…Red points are exons with PSI decreasing by at least 5% in at least 1 tumor type. …”

Cell viability as measured by MTT absorbance (abs) at 570nm, LDH release and intracellular NAD levels of microglial cells after 48 hour incubation in pooled, non heat inactivated a... by Tharusha Jayasena (704509)